RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.
A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
RightAnswer Proprietary Data Sources:
All Other Data Sources:
Other Government Links Searched via RegsKnowledge:
State Environmental Regulations
Example Content from MEDITEXT for 110942-02-4:
Please note: this is an extract of information from a larger document. Full document and details are available by subscription.
ACUTE EXPOSURE INFORMATION
- WITH THERAPEUTIC USE
- Capillary leak syndrome usually develops within a few hours of the start of aldesleukin (IL-2) therapy and begins to resolve within a few hours of its discontinuation. Common manifestations include hypotension, tachycardia and oliguria. Generalized edema, weight gain, pleural effusions, pulmonary edema, ascites, renal insufficiency and confusion may also develop.
- Nausea, vomiting and diarrhea develop in most patients and diarrhea may be severe. Anemia, leukopenia and thrombocytopenia may develop but are rarely severe. Fever and chills are also common during therapy.
- Increased serum bilirubin is common, increased aminotransferase levels develop less often and both usually resolve after therapy is discontinued. Electrolyte disturbances (hypomagnesemia, hypocalcemia, hypokalemia, and hypophosphatemia) develop in about 10% of patients but are rarely severe.
- WITH POISONING/EXPOSURE
- Overdose information is limited. Exceeding the recommended dose has ben associated with a more rapid onset of typical adverse effects.
© 2011-2020 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.